AbbVie licenses anti-COVID-19 antibody for clinical development

By The Science Advisory Board staff writers

December 15, 2020 -- Harbour BioMed and Utrecht University have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie. AbbVie has initiated a phase I clinical trial of the antibody for the prevention and treatment of COVID-19, initially in the U.S. with the goal of expanding into Europe.

The antibody was discovered using fully human transgenic Harbour mice. The antibody targets a conserved region of the SARS-CoV-2 spike protein and the preclinical data indicate that the antibody can target current strains but also potential escape mutants.

The phase I trial will be a randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single ascending doses of the antibody in adults hospitalized with COVID-19. Three different doses will be testing on 24 patients.

Under the license agreement, AbbVie will conduct clinical development of ABBV-47D11, and if successful, will manufacture and commercialize the product worldwide. AbbVie will pay Harbour and Utrecht a one-time license fee, certain development, regulatory, and sales milestone payments, and tiered royalties on commercial net sales of the antibody.

Erasmus University Medical Center (Erasmus MC) was involved in the fundamental science but is not involved in the license agreement. Financial terms were not disclosed.

Harbour BioMed, Hualan Genetic partner on antibody programs
Harbour BioMed and Hualan Genetic Engineering have entered a strategic partnership agreement to develop three proprietary monoclonal and bispecific antibodies...
Harbour BioMed, Vir to develop new therapies
Harbour Biomed and Vir Biotechnology have partnered to research and develop novel immuno-oncology and infectious disease therapies.
Companies work to develop combo mAb, NK cell COVID-19 therapy
A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal...
AbbVie licenses antibody technology for COVID-19
AbbVie, Harbour BioMed, Utrecht University, and Erasmus Medical Center announced that they have entered into a collaboration to develop a novel antibody...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter